Cargando…

Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric Population

Ethical regulations and limited paediatric participants are key challenges that contribute to a median delay of 6 years in paediatric mAb approval. To overcome these barriers, modelling and simulation methodologies have been adopted to design optimized paediatric clinical studies and reduce patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Andrew, Sharma, Pradeep, Stepanov, Oleg, Reddy, Venkatesh Pilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223156/ https://www.ncbi.nlm.nih.gov/pubmed/37242793 http://dx.doi.org/10.3390/pharmaceutics15051552

Ejemplares similares

Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
por: Temrikar, Zaid H., et al.
Publicado: (2020)

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction
por: Gill, Jaidip, et al.
Publicado: (2022)

394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
por: Clegg, Lindsay E, et al.
Publicado: (2023)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Therapeutic Applications of Monoclonal Antibodies
por: Berger, Mitchell, et al.
Publicado: (2002)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
por: Basu, Sumit, et al.
Publicado: (2020)

The pharmacology and therapeutic applications of monoclonal antibodies
por: Castelli, María Sofía, et al.
Publicado: (2019)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations
por: Haraya, Kenta, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Therapeutic monoclonal antibody for sporotrichosis
por: Almeida, Sandro R.
Publicado: (2012)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice
por: Liu, Shufang, et al.
Publicado: (2023)

Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform
por: Karelina, Tatiana, et al.
Publicado: (2021)

Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
por: Bussing, David, et al.
Publicado: (2021)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
por: Ovacik, Meric, et al.
Publicado: (2018)

Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes
por: Cataldi, Mauro, et al.
Publicado: (2017)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19
por: Asdaq, Syed Mohammed Basheeruddin, et al.
Publicado: (2021)

Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing
por: Cai, Weiguo, et al.
Publicado: (2020)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
por: Jones, Hannah M., et al.
Publicado: (2019)

Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody
por: Falck, David, et al.
Publicado: (2020)

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
por: Gill, Jaidip, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia
por: Quattrone, Martina, et al.
Publicado: (2023)

A Simple Method for the Prediction of Therapeutic Proteins (Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins) for First-in-Pediatric Dose Selection: Application of Salisbury Rule
por: Mahmood, Iftekhar
Publicado: (2022)

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy
por: Oi Yan Chan, Joyce, et al.
Publicado: (2022)

1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
por: Maas, Brian, et al.
Publicado: (2018)

383. Pharmacokinetics and Safety in Healthy Adults of RSM01, a Novel RSV Monoclonal Antibody, and Population PK Modeling to Support Pediatric Development
por: Levi, Micha, et al.
Publicado: (2023)

Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory
por: Ladwig, Paula M., et al.
Publicado: (2017)

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope
por: Kizhedath, Arathi, et al.
Publicado: (2016)

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2021)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
por: Pan, Xian, et al.
Publicado: (2021)

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
por: Haraya, Kenta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2hko9c3jkbkm17c1e7mq9ttgna